Lifetime risk of developing coronary heart disease

Lancet

Volumn 353, Issue 9147, 1999, Pages 89-92

  Lloyd Jones, Donald M ^a,b   Larson, Martin G ^a,c   Beiser, Alexa ^d   Levy, Daniel ^a,b,c,e  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e FRAMINGHAM HEART STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEALTH PROMOTION; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIFE TABLE; LIFESPAN; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE;

EID: 0033537343     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)10279-9     Document Type: Article

References (28)

1. Garfinkel L Probability of developing or dying of cancer United States, 1991. Stat Bull Metrop Insur Co. 76:1995;31-37.
2. Schouten LJ, Straatman H, Kiemeney LA, Verbeek AL Cancer incidence: life table risk versus cumulative risk. J Epidemiol Community Health. 48:1994;596-600.
3. Cummings SR, Black DM, Rubin SM Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med. 149:1989;2445-2448.
4. Seshadri S, Wolf PA, Beiser Aet al. Lifetime risk of dementia and Alzheimer's disease: the impact of mortality on risk estimates in the Framingham Study. Neurology. 49:1997;1498-1504.
5. Feuer EJ, Wung L, Boring CC, Flanders WD, Timmel MJ, Tong T The lifetime risk of developing breast cancer. J Natl Cancer Inst. 85:1993;892-897.
6. National Heart, Lung, and Blood Institute. Morbidity and mortality: 1996 chartbook on cardiovascular, lung, and blood diseases. Bethesda, MD: National Institutes of Health, 1996.
7. Murray CJL, Lopez AD Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 349:1997;1269-1276.
8. Murray CJL, Lopez AD Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 349:1997;1498-1504.
9. Fraser GE, Lindsted KD, Beeson WL Effect of risk factor values on lifetime risk of and age at first coronary event: the Adventist Health Study. Am J Epidemiol. 142:1995;746-758.
10. Grady D, Rubin SM, Petitti DBet al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 117:1992;1016-1037.
11. Dawber TR, Meadors GF, Moore FE Epidemiologic approaches to heart disease: the Framingham study. Am J Public Health. 41:1951;279-286.
12. Gordon T, Moore FE, Shurtleff D, Dawber TR Some methodologic problems in the long-term study of cardiovascular disease: observations on the Framingham Study. J Chronic Dis. 10:1959;186-206.
13. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol. 110:1979;281-290.
14. Abbott RD, McGee DL. The Framingham Study: an epidemiological investigation of cardiovascular disease, section 37 - the probability of developing certain cardiovascular diseases in eight years at specified values of some characteristics. Bethesda, MD: National Heart, Lung, and Blood Institute, 1987.
15. Gaynor JJ, Feuer EJ, Tan CC On the use of cause-specific failure and conditional failure probabilities. J Am Stat Assoc. 88:1993;402-409.
16. National Center for Health Statistics. Healthy people 2000 review, 1995-96. Hyattsville, MD: Public Health Service, 1996.
17. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 157:1997;2413-2446.
18. Pearson TA, Laurora IM. Attainment of LDL-cholesterol goals in a national sample: results from the Lipid Treatment Assessment Project (L-TAP). J Am Coll Cardiol 1998; 31 (2 Suppl A): 88A (abstr).
19. Murray CJL, Lopez AD Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 349:1997;1436-1442.
20. Stampfer MJ, Colditz GA Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 20:1991;47-55.
21. Stampfer MJ, Colditz GA, Willett WCet al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses Health Study. N Engl J Med. 325:1991;756-762.
22. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-64.
23. Staessen JA, Fagard R, Thijs Let al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 350:1997;757-764.
24. Downs JR, Clearfield M, Weis Set al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 279:1998;1615-1622.
25. Shepherd J, Cobbe SM, Ford Iet al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med. 333:1995;1301-1307.
26. Burt VL, Whelton P, Roccella EJet al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 25:1995;305-313.
27. American Heart Association. 1998 heart and stroke statistical update. Dallas, TX: American Heart Association, 1998.
28. National Center for Health Statistics. Health, United States, 1996-97. Hyattsville, MD: US Public Health Service, 1997.